The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs. It also clarifies what Schedule III does not show about cannabis safety, dosing, or effectiveness for specific conditions.
Cannabinoids and Chronic Pain: 2025 Evidence Review
A 2025 narrative review evaluates the evidence for cannabinoids in chronic pain management, summarizing modest analgesic benefits, meaningful adverse effects, and the regulatory barriers that limit clinical implementation.
Cannabis Rescheduling Is Not the Story People Think It Is
The cannabis rescheduling clinical impact is being widely misunderstood. While federal policy shifts from Schedule I to Schedule III signal progress, they do not define how cannabis should be used in medical care. This analysis clarifies what changes, what does not, and what clinicians and patients should actually take from this moment.
Cannabis Brain Health and Aging Brain: Beyond the Headlines
Public discussions regarding cannabis brain health and aging often fail to distinguish between recreational adolescent use and late-life therapeutic guidance. This clinical review breaks down recent data to show why the exposure definition and habit structure are critical to understanding cognitive outcomes. Discover how structured medical oversight can shift the impact of cannabis from cognitive friction to functional support.
Cannabis Nebulizer Patent (US 2017/0281701): Evidence Analysis
A 2017 US patent proposes liposomal cannabis formulations for vibrating mesh nebulizers. We analyze what the document claims versus what remains unproven.
Extended Pulmonary Drug Exposure: Inhaled Medicine Strategies Reviewed
Review of pharmaceutical strategies to extend pulmonary drug exposure for inhaled medicines, covering formulation science, preclinical evidence, and clinical…
CBD for Brain Tumor Anxiety: What This Trial Found
CBD for brain tumor anxiety is an appealing idea, especially for patients facing heavy emotional and neurologic burdens. This early-terminated randomized crossover trial did not show benefit over placebo for anxiety or depressive symptoms in adults with primary brain tumors. The study is still useful because it helps separate hope, signal, and proof in a vulnerable clinical population.
Medical Cannabis Counseling for Older Adults: What Physicians Are Telling Patients
Medical cannabis counseling for older adults is becoming more important as more seniors ask clinicians about cannabis for pain, sleep, and anxiety. This study shows that many physicians are having these conversations, but most still do not feel fully prepared to give detailed, age-specific guidance. For patients and providers alike, the message is clear: interest is rising faster than clinical education.
Metabolic Health Explained
CED Clinical Guide Metabolic Primer General-public explainer Built to clarify metabolism and GLP-1 physiology without flattening the science. Clinical Insight | CED Clinic Metabolism is often discussed in language that is too...
Semaglutide vs Tirzepatide Comparison: Which Works Better and Why
Semaglutide and tirzepatide are often discussed like cousins in the same family photo, but they are not interchangeable. Tirzepatide currently has the stronger average weight-loss data, while semaglutide keeps several meaningful clinical advantages that still matter quite a bit in real practice. If you are trying to make sense of Wegovy vs Zepbound without getting lost in hype, this is the comparison worth reading.